23 nov: Aktier/åbning: Indekstunge aktier trækker eliteindeks i rødt
23 nov: Danmark/økonomer: Ledighedstal tegner dystert billede
23-11-2016 10:06:12

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Relateret indhold
20 apr - 
Fredagens aktier: Mærsk i fuld fart frem - Vestas og Ba..
20 apr - 
Bavarian: Udenlandske kapitalfonde øger væddemålet på k..
19 apr - 
Torsdagens aktier: Mærsk og NKT steg til tops på nyheds..
Relateret debat
10:18 - 
Årsagen til jeg spørger er at jeg kan se at der rent fa..
21 apr - 
He he ;)
21 apr - 
Ikke helt sikker på jeg helt forstår det du skriver...m..

COPENHAGEN, Denmark, November 23, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 4,197,860 as a consequence of employees' exercise of warrants.

The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 286,283 shares at DKK 73.90 and 133,503 shares at DKK 59.10. The total proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 29 million.

The new shares, which will rank pari passu in all respects with existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.

Pursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on Issuers' Disclosure Obligations, it is hereby announced, that the total nominal value of Bavarian Nordic A/S' share capital after the capital increase is DKK 313,538,460, which is made up of 31,353,846 shares of a nominal value of DKK 10 each, corresponding to 31,353,846 votes.

The revised Articles of Association will be published separately and will subsequently be available on the Company's website.

The content of this announcement does not affect the Company's expectations for the financial results for 2016.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 29 / 2016

2016-29-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 771532.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
18 apr
BAVA
Jeg tror nok der er nogen, der sidder lidt længere ude på stolen i dag. Det skulle ikke undre mig om..
11
17 apr
BAVA
Aamund har alle dage været rigtig god til at tale.........for sin syge moster. Jeg har ingen fidus t..
11
17 apr
BAVA
Nu har AA aldrig været kendt for, at være ramt af biotek aktie-pessimisme, så med en skovl salt til,..
9
21 apr
BAVA
Er en velkendt måde for spekulanter og pensionskasser at tjene penge på. Hvis frosten kommer tjener ..
7
20 apr
BAVA
Det er ikke hans skyld. Det er disse shortere der bare skal have dens mindste anledning til at sælge..
5
18 apr
BAVA
@Henry1, jeg må indrømme, at det af og til er bare en anelse trættende at læse dine Bavarian indlæg...
5
16 apr
BAVA
Sidder og læser årsrapporten på BAVAs hjemmeside før i morgen. Og i denne er der på ingen måde lagt ..
5
18 apr
BAVA
GSA Capital Partners LLP holds a short position at 0.54 % in shares issued by Bavarian Nordic A/S Gi..
4
17 apr
BAVA
Ja kan ikke rigtig lide AA kommentar omkring det kortsigtet, det langsigtet er jeg 100% enig i.   Ko..
4

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

20-04-2018 12:49:56
Den amerikanske Vestas-konkurrent General Electric (GE) har solgt flere vindmøller i første kvartal, men selskabet melder om fortsat prispres i branchen. GE havde i de første tre måneder af 2018 en ordreindgang på 936 vindmøller mod 589 i samme periode sidste år. Selskabet oplyser ikke størrelsen på de solgte møller, men skriver i en kommentar, at det har haft en stærk vækst i USA målt på megawatt..

Brøndby-aktien banker til vejrs efter sejr over guldrival

20-04-2018 09:20:41
Aktien i Brøndby IF bliver sendt til vejrs med en stigning på 13,6 pct. til 1,25 kr. fredag morgen, efter at fodboldklubben torsdag aften vandt 3-2 på udebane over FC Midtjylland i Alka Superligaen.Med sejren fastholder Brøndby IF sin førsteplads i Alka Superligaen og har nu tre point ned til netop FC Midtjylland på andenpladsen. Der mangler at blive spillet seks runder, før sæsonen er slut i Alka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 169,70 -3,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. april 2018 16:16:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180417.1 - EUROWEB1 - 2018-04-22 16:16:06 - 2018-04-22 16:16:06 - 1 - Website: OKAY